Many factors contribute to improved prognosis for patients with heart failure: Reply
We thank Str€ omberg and Dahlstr€ om for highlighting the structured clinical care programmes often used in Swedish hospitals. In our discussion, we clearly point out that we do not know why the prognosis for patients hospitalised for heart failure has improved. 1 We discuss different possibilities and it is very likely that improved medical treatments of hypertension, ischaemic heart disease and heart failure, which have been demonstrated in big outcome studies, is of great importance for the beneficial results. We also discuss how to provide these treatments in a clinical setting. The evidence for benefit from special care programmes of patients with heart failure is limited but it is reasonable to believe that an organised treatment regimen is favourable as this care will help to disseminate evidence-based treatments. We referred to home-based care because it shows one extreme possibility. 2 More recent findings from Sweden with a limited number of patients support the value of nurse-led clinics. 3 Nurse-led clinics are also recommended in the ESC guidelines. 4 However, as discussed elsewhere, we do not know why structured care may be successful. 5 The content of the components of structured care would be important to assess for our understanding of the importance of this type of care.
Until now, we have reason to speculate upon the importance of this care but as Str€ omberg and Dahlstr€ om point out, the results are not unambiguous.
Accordingly, we do believe that nurseled clinics are important. However, we do not know why this care may be beneficial and we do not know the relation between special care and the documented effects of medicines. Until then, each organisation has to find the optimal way to provide evidence-based treatments. In Sweden, nurse-led clinics in this context have now been established.
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Annika 
Contrast agent nephropathy

Dear Sir
The meta-analysis in the Lancet 23 August 2003 1 concluded that acetylcysteine significantly reduces the risk of contrast nephropathy in patients with chronic renal insufficiency, and that the relative risk of contrast nephropathy was not related to the amount of radio contrast media given. Yet, as we see from a recent issue of the European Heart Journal, doubt seems to remain concerning both questions [2] [3] [4] . Is it not time to do a large multi-centre trial?
